Biotechnology

BAO PHARMA-B

Shanghai Baoji Pharmaceutical Holds 2026 Annual General Meeting

Shanghai Baoyi Pharmaceutical Chairman Liu Yanjun Plans to Increase Holdings

BioTech Pharma's Recombinant Ulinastatin Clinical Trial Application Accepted by NMPA

Baoji Pharmaceutical's KJ017 Approved for Market, Driving Valuation Recovery in Hong Kong's Biopharmaceutical Sector

Chinese Innovative Drug Industry Experiences a Value Reappraisal, Baoyi Pharmaceutical Benefits from Favorable Policies

Shanghai Bioej Pharmaceutical Obtains Marketing Approval for KJ017 Human Hyaluronidase Injection

BAO PHARMA-B released FY2025 Annual Earnings on March 26, 2026 (BJT), with actual revenue of HKD 53.73 M and EPS of HKD -1.4886

BAO PHARMA-B released FY2025 Q4 earnings on March 26, 2026 (BJT) with actual revenue HKD 0 and actual EPS HKD 0

BAO PHARMA-B released FY2025 9 Months Earnings on March 26, 2026 (BJT), with actual revenue of HKD 49.38 M and EPS of HKD -1.0848

BAO PHARMA-B released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.917 M, actual EPS HKD -0.3966

Baoyi Pharmaceutical Announces 2025 Annual Results and Advances Core Product Development

Baoji Pharmaceutical-B Announces Annual Results: Revenue Up 698%, Loss Widened

Bioinship KJ103 Completes Phase III Clinical Trial and Plans to Submit NDA

BAO PHARMA-B to Release FY2025 Earnings on March 26, 2026 (BJT)

Shanghai Baoji Pharmaceutical Obtains NMPA Approval for KJ101 Clinical Trials

Biojoys Pharma Donates HKD 1 Million to Help Fire Victims

BAO PHARMA-B released FY2024 9 Months Earnings on December 2, 2025 (BJT), with actual revenue of HKD 4.197M and EPS of HKD -1.0908

BAO PHARMA-B released FY2024 Q2 earnings on December 2, 2025 (BJT), with actual revenue of HKD 801.06 K and EPS of HKD -0.3453

BAO PHARMA-B released FY2023 Annual Earnings on December 2, 2025 (BJT), actual revenue HKD 7.61 M, actual EPS HKD -0.6962

BAO PHARMA-B released FY2025 Q1 earnings on December 2, 2025 (BJT), actual revenue HKD 22.49 M, actual EPS HKD -0.3403

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02565

02659

02575

01796

In the past hour, the Hong Kong stock market has shown a clear divergence, with the strong performance of the pharmaceutical sector attracting a significant inflow of funds, particularly in stocks like PEGBIO CO-B and BAO PHARMA-B, which have seen notable gains, indicating an increase in short-term enthusiasm. Meanwhile, technology stocks appear relatively weak, with the declines of METASPACEX and Yimu Group drawing market attention, suggesting a rapid switch of funds between different sectors. Overall volatility is high, and the sentiment of short-term traders is fluctuating, with a faster market rhythm. The stock with the largest movement in the past hour, PEGBIO CO-B, has surged by 23.15%, rapidly attracting funds under the influence of the pharmaceutical sector, leading to heightened short-term sentiment and drawing the attention of many investors. The strong performance of this stock seems to inject vitality into the entire sector, driving up other related stocks. Strong stocks include: 1. BAO PHARMA-B: up 18.49%, with continuous inflow of funds against the backdrop of increased market enthusiasm, showing impressive short-term performance. 2. XUANZHUBIO-B: up 16.00%, recent strong trends reflect market confidence in its future development. 3. Jingjiu Kangliao: up 15.87%, gaining favor from investors as the pharmaceutical sector becomes active. 4. Zhongke Group Holdings - New: up 15.38%, with significant short-term fund support amid high market sentiment. 5. Silu Di Pharmaceutical Co., Ltd.: up 15.12%, with the stock's rise reflecting optimistic expectations for the pharmaceutical industry

HK Stock Alerts

PEGBIO CO-B

XUANZHUBIO-B

METASPACEX

THAC GROUP

3D MEDICINES

CHINA STAR ENT

Hong Kong Stock Movement Update: Biopharmaceutical stocks rebound strongly, PEGBIO CO-B rises 23%, METASPACEX falls 15%

02552

03069

Yesterday, HUA MEDICINE-B triggered a golden cross signal on the daily MACD zero axis in the Hong Kong stock market, with a trading volume of approximately HKD 4.68 million, which is considered a normal high level for this unprofitable biotech stock. The confirmation of the golden cross above the zero axis on the MACD indicates that a medium-term bullish pattern is beginning to take shape, and buying pressure is accumulating in stages. HUA MEDICINE focuses on the research and development of innovative drugs for diabetes, and its stock price has gradually rebounded from a state of extreme sluggishness, with initial signs of a bottom forming. On the news front, the overall biotech sector in the Hong Kong stock market has recently stabilized after a decline. The news that BAO PHARMA has been included in the MSCI Global Small Cap Index has attracted market attention, indicating a renewed recognition of the value of innovative pharmaceutical companies by international capital. The trading activity of the group of Hong Kong 18A biotech companies has recently increased, with some stocks experiencing unusual capital movements. In addition, frequent mergers and acquisitions in the global pharmaceutical industry have heightened market attention to the pipeline value of unprofitable biotech companies, which could serve as a potential catalyst for R&D-focused pharmaceutical companies like HUA MEDICINE. From a technical perspective, HUA MEDICINE-B has limited liquidity, with a low average daily trading volume, so the reference value of technical signals needs to be assessed in conjunction with changes in trading volume. If the trading volume can maintain above HKD 4 million in subsequent trading days and is accompanied by a positive closing price, the reliability of the signal will be enhanced. The overall trend of the biotech sector and the capital flow of similar 18A stocks are important references. The short-term trend is biased towards bullish but should be approached with caution, as technical signals for small-cap, low-liquidity stocks can easily be distorted by large single orders. Attention should be paid to the company's pipeline progress and changes in sector sentiment

Technical Forecast

HUA MEDICINE-B

CAM HSBIOTECH

Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks?

BAO PHARMA-Bsaw a significant drop of 64.06%, closing at HKD26.92 after opening down 0.4%. The stock experienced heavy turnover of 24.2661 million shares, totaling HKD739 million. Despite a remarkable rise to HKD206 in late February, profit-taking amid earnings pressure led to the decline. The company reported a revenue of RMB49.156 million last year, a 698% increase YoY, but losses widened to RMB395 million. BAO PHARMA-B was included in the Hong Kong Stock Connect on March 9.

AASTOCKS News

BAO PHARMA-B  Plunges 64% on Heavy Turnover; Included in Hong Kong Stock Connect in Early Mar

02635

00819

02591

01858

06869

02442

02650

01907

00631

BAO PHARMA-B(02659) fell 65.55%, with a trading turnover 785.1 Million HKD, and a year-to-date fell 66.7%. NUOBIKAN(02635) fell 31.2%, with a trading turnover 281.8 Million HKD, and a year-to-date fell 47.2%. TIANNENG POWER(00819) fell 27.25%, with a trading turnover 720.0 Million HKD, and a year-to-date fell 19%.

Top Gainers&Losers

NUOBIKAN

TIANNENG POWER

INNOGEN-B

CHUNLI MEDICAL

YOFC

EASY SMART GP

ZHIDA TECH

CHINA RISUN GP

SANY INT'L

Top 10 HK Stock Losers (4.30)

BAO PHARMA-B (2659.HK) current price is 27.500, down 63.28% for the day, hitting a historical low during the session, with a market capitalization of HKD 8.99 billion. The company focuses on the research and development of macromolecular drugs, with core products such as KJ017. Today, BAO PHARMA-B has the largest decline among the top ten stocks in the Hong Kong market, with significant selling pressure. There are no major negative news reports, and short-term sentiment is dominating the sharp decline in stock price

Movers Alert

Bojun Pharma-B (2659.HK) Hits All-Time Low, Drops Over 60%

BAO PHARMA-B fell 49.69%; Innovent Biologics rose 4.18%, with a transaction volume of HKD 970 million; CanSino Biologics rose 0.95%, with a transaction volume of HKD 586 million; 3SBio rose 3.78%, with a transaction volume of HKD 440 million; BeiGene fell 2.57%, with a market value of HKD 269 billion

INNOVENT BIO

AKESO

3SBIO

BEONE MEDICINES

Hong Kong Stock Movement: BAO PHARMA-B plummets 49.69%, no significant news but shows volatility, what is driving the market sentiment?

01471

02655

01133

09878

03881

02656

08279

06687

ZHONGMIAO(01471) fell 33.38%, with a trading turnover 3.6 Million HKD, and a year-to-date rose 78%. BAO PHARMA-B(02659) fell 13.43%, with a trading turnover 163.4 Million HKD, and a year-to-date rose 28.4%. GUOXIA TECH(02655) fell 11.08%, with a trading turnover 110.4 Million HKD, and a year-to-date rose 29.7%.

ZHONGMIAO

GUOXIA TECH

HARBIN ELECTRIC

HUITONGDA NET

CIDI

160 HEALTH

AGTECH HOLDINGS

JST GROUP

Top 10 HK Stock Losers (4.10)

Shanghai Bao Pharmaceuticals has received approval from China's National Medical Products Administration for its Human Hyaluronidase for Injection (KJ017). This product, designed to enhance subcutaneous infusion of solutions, offers a safer alternative to traditional animal-derived hyaluronidase by reducing immunogenicity risk and improving consistency. The approval strengthens the company's position in advanced injectable delivery technologies, targeting patients with difficult intravenous access. Shanghai Bao Pharmaceuticals is a Hong Kong-listed drug manufacturer focused on innovative injectable therapies.

Tip Ranks

Shanghai Bao Pharma Wins NMPA Nod for Recombinant Human Hyaluronidase Injection

BAO PHARMA-B(02659.HK)